Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

New diabetes drug Mounjaro is more effective for weight loss that the popular drug Ozempic, an analysis found. The analysis, conducted by Truveta Research, found that patients taking Eli Lilly’s diabetes drug Mounjaro were “significantly more likely” to experience 5 percent,

A new study found that Mounjaro, which is FDA-approved to treat type 2 diabetes but used off-label for weight loss, works better than competing weight loss medication Ozempic